Advanced search
Publication Cover
Acta Cardiologica Volume 62, 2007 - Issue 3
Submit an article Journal homepage
11
Views
0
CrossRef citations to date
0
Altmetric
Articles

Serum paraoxonase 1 activity and oxidative markers of LDL in patients with cardiac syndrome X

Meral KayikciogluDepartments of Cardiology, Ege University School of Medicine, Izmir, Turkey.Correspondence[email protected]
,
Serkan SaygiDepartments of Cardiology, Ege University School of Medicine, Izmir, Turkey.
,
Elif AzarsizDepartments of Biochemistry, Ege University School of Medicine, Izmir, Turkey.
,
Levent H. CanDepartments of Cardiology, Ege University School of Medicine, Izmir, Turkey.
,
Hakan KultursayDepartments of Cardiology, Ege University School of Medicine, Izmir, Turkey.
&
Eser Yildirim SözmenDepartments of Biochemistry, Ege University School of Medicine, Izmir, Turkey.
Pages 245-249 | Received 10 May 2006, Accepted 06 Mar 2007, Published online: 23 May 2017

References

  • Kaski JC, Aldama G, Cosin-Sales J. Cardiac syndrome X. Diagnosis, pathogenesis and management. Am J Cardiovasc Drugs 2004; 4: 179–94.
  • Joannides R, Haefeli WE, Linder L, Richard V, Bakkali EH, Thuillez C, Luscher TF. Nitric oxide is responsible for flow-dependent dilatation of human peripheral conduit arteries in vivo. Circulation 1995; 91: 1314–9.
  • Azarsiz E, Kayikcioglu M, Payzin S, Sözmen EY. PON1 activities and oxidative markers of LDL in patients with angiographically proven coronary artery disease. Int J Car-diol 2003; 91: 43–51.
  • Kayikcioglu M, Payzin S, Yavuzgil 0, Kultursay H, Can LH, Soydan I. Benefits of statin treatment in cardiac syndrome- X. Eur Heart J2003; 24: 1999-2005.
  • Eckerson HW, Wyte C, LaDu BN. The human serum paraoxonase/arylesterase polymorphism. Am J Hum Genet 1983; 35: 1126–38.
  • Sözmen EY, Sözmen B, Girgin FK, Delen Y, Azarsiz E, Erdener D, Ersöz B. Antioxidant enzymes and paraoxonase show co-activity in preserving LDL from oxidation. Clin Exp Med 2001; 1: 195–9.
  • Celermajer DS, Sorensen KE, Gooch VM, Spiegelhalter DJ, Miller OI, Sullivan ID, Lloyd JK, Deanfield JE. Non-inva-sive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992; 340: 1111–5.
  • Mackness MI, Durrington PN, Mackness B. The role of paraoxonase 1 activity in cardiovascular disease: potential for therapeutic intervention. Am J Cardiovasc Drugs 2004; 4: 211–7.
  • Aviram M, Rosenblat M, Scott B, Drogul J, Sorenson R, Bisgaier CL, Newton RS, La Du B. Human serum paraox-onase (PON1) is inactivated by oxidised low density lipopro-tein and preserved by antioxidants. Free Rad Biol Med 1999; 26: 892–904.
  • Aikawa K, Saitoh S, Muto M, Osugi T, Matsumoto K, Onogi F, Maehara K, Yaoita H, Maruyama Y. Effects of antioxidants on coronary microvascular spasm induced by epicardial coronary artery endothelial injury in pigs. Coron Artery Dis 2004; 15: 21–30.
  • Iuliano L, Colavita AR, Leo R, Pratico D, Violi F. Oxygen free radicals and platelet activation. Free Radic Biol Med 1997; 22: 999–1006.
  • Lin CP, Lin WT, Leu HB, Wu TC, Chen JW. Differential mononuclear cell activity and endothelial inflammation in coronary artery disease and cardiac syndrome X. Int J Car-diol 2003; 89: 53–62.
  • Pasqualini L, Cortese C, Marchesi S, Siepi D, Pirro M, Vaudo G, Liberatoscioli L, Gnasso A, Schillaci G, Man-narino E. Paraoxonase-1 activity modulates endothelial func-tion in patients with peripheral arterial disease. Atheroscle-rosis 2005; 183: 349–54.
  • Pizzi C, Manfrini 0, Fontana F, Bugiardini R. Angiotensin-converting enzyme inhibitors and 3-hydroxy-3-methylglu-taryl coenzyme A reductase in cardiac Syndrome X: role of superoxide dismutase activity. Circulation 2004; 109: 53–8.
  • Fabian E, Varga A, Picano E, Vajo Z, Ronaszeki A, Csanady M. Effect of simvastatin on endothelial function in cardiac syndrome X patients. Am J Cardiol 2004; 94: 652–5.
  • Kural BY, Orem C, Uydu HA, Alver A, Orem A. The effects of lipid-lowering therapy on paraoxonase activities and their relationships with the oxidant-antioxidant system in patients with dyslipidemia. Coron Artery Dis 2004; 15: 277–83.
  • Bauters C, Amant C, Boullier A, Cabrol P, McFadden E, Duriez P, Bertrand ME, Amouyel P. Paraoxonase polymor-phism (G1n192Arg) as a determinant of the response of human coronary arteries to serotonin. Circulation 2000; 101: 740–3.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Committed to improving the lives of patients with Type 2 Diabetes, Heart Failure and Chronic Kidney Disease.
A bold vision to stop cardiovascular disease from being a leading cause of death.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.